This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
ALKSPositive Net Change VRTXPositive Net Change EXASPositive Net Change CRSPNegative Net Change
biotechs
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AZNPositive Net Change BMYPositive Net Change MRKPositive Net Change MRNANegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals vaccines
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
BIIBPositive Net Change LLYPositive Net Change SUPNPositive Net Change SAGENo Net Change
biotechs
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Ekta Bagri
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
BMYPositive Net Change PFEPositive Net Change BNTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
by Shrabana Mukherjee
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
GHMNegative Net Change HWKNNegative Net Change KALAPositive Net Change ARQNegative Net Change
biotechs industrial-products
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
by Ahan Chakraborty
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
SNYPositive Net Change RHHBYNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
by Zacks Equity Research
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
REGNPositive Net Change VRTXPositive Net Change MRNANegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
ALKSPositive Net Change AMRNPositive Net Change EXASPositive Net Change AKRONegative Net Change
biotechs
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSPositive Net Change INCYPositive Net Change EXASPositive Net Change AKRONegative Net Change
biotechs
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
RDYNegative Net Change MRKPositive Net Change AMGNPositive Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
by Zacks Equity Research
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
AGENNegative Net Change AMRNPositive Net Change VKTXPositive Net Change AKRONegative Net Change
biotechs earnings medical
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechs earnings medical pharmaceuticals
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
BMYPositive Net Change JNJPositive Net Change KROSNo Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
by Zacks Equity Research
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
ALKSPositive Net Change INCYPositive Net Change EXELPositive Net Change AKRONegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
by Ahan Chakraborty
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
by Sundeep Ganoria
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
by Zacks Equity Research
AstraZeneca unveils a $50 billion U.S. manufacturing expansion plan, anchored by a Virginia facility to boost drug output and counter tariff headwinds.
AZNPositive Net Change NVSPositive Net Change JNJPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
by Zacks Equity Research
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
ALKSPositive Net Change JAZZPositive Net Change AXSMPositive Net Change ARVNNegative Net Change
biotechs
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
by Zacks Equity Research
Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.
RHHBYNegative Net Change BAYRYPositive Net Change SRPTNegative Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
by Sundeep Ganoria
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
BIIBPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
by Zacks Equity Research
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
RHHBYNegative Net Change BAYRYPositive Net Change SRPTNegative Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
by Zacks Equity Research
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
JNJPositive Net Change BAYRYPositive Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
by Zacks Equity Research
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
GSKPositive Net Change EXASPositive Net Change VKTXPositive Net Change AKRONegative Net Change
biotechs earnings medical
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
by Zacks Equity Research
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
RCKTNegative Net Change ARVNNegative Net Change AKRONegative Net Change KROSNo Net Change
biotechs